4-(吗啉-4-羰基)苯基硼酸 | 389621-84-5

• 物质功能分类: 化学试剂 - 有机试剂 - 硼酸
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 中文名称: 4-(吗啉-4-羰基)苯基硼酸
• 中文别名: 4-(吗啉-4-羰基)苯硼酸
• 英文名称: 4-(morpholine-4-carbonyl)phenylboronic acid
• 英文别名: [4-(morpholine-4-carbonyl)phenyl]boronic acid
• CAS: 389621-84-5
• 化学式: C₁₁H₁₄BNO₄
• mdl: MFCD03411952
• 分子量: 235.047
• InChiKey: KMNLIQJXZPBCDU-UHFFFAOYSA-N

物化性质

• 熔点：
  126-132°C
• 沸点：
  481.6±55.0 °C(Predicted)
• 密度：
  1.30±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.44
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  70
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
4-(Morpholine-4-carbonyl)phenylboronic acid
Product Name:
Synonyms: 4-(4-Boronobenzoyl)morpholine; (4-boronophenyl)(morpholin-4-yl)methanone

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
4-(Morpholine-4-carbonyl)phenylboronic acid
Ingredient name:
CAS number: 389621-84-5

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C11H14BNO4
Molecular weight: 235.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(吗啉-4-羰基)苯基硼酸 在 potassium hydrogen difluoride 作用下， 以 甲醇 、 乙醇 、 水 为溶剂， 反应 0.5h， 以0.57 g的产率得到potassium (4-(morpholine-4-carbonyl)phenyl)trifluoroborate
  参考文献：
  名称：

  镍催化四羟基二硼 [B2(OH)4] 卤化物和拟卤化物的硼化反应

  摘要：

  芳基硼酸作为试剂和目标结构在各种有用的应用中变得越来越重要。最近，报道了使用原子经济的四羟基二硼（BBA）试剂在钯催化下合成芳基硼酸。钯的高成本，加上钯和铜催化工艺的一些限制，促使我们开发一种替代方法。因此，已经制定了使用四羟基二硼（BBA）对芳基和杂芳基卤化物和拟卤化物进行镍催化的硼基化反应。该反应被证明具有广泛的官能团耐受性并适用于许多杂环体系。据我们所知，这里提供的例子代表了在室温下进行的唯一有效的镍催化宫浦硼化反应。

  DOI：

  10.1021/jo401104y
• 作为产物：
  描述：

  4-(4-碘苯甲酰基)吗啉 在 双二甲胺基乙基醚 、 异丙基氯化镁 、 硼酸三甲酯 、 盐酸 、 水 作用下， 以 四氢呋喃 为溶剂， 反应 2.67h， 生成 4-(吗啉-4-羰基)苯基硼酸
  参考文献：
  名称：

  [EN] CARBAZOLE AND CARBOLINE KINASE INHIBITORS
  [FR] CARBAZOLE ET INHIBITEURS DE LA CARBOLINE KINASE

  摘要：

  本发明提供了式（I）的化合物及其药用可接受的盐。式（I）的化合物抑制Jak2的酪氨酸激酶活性，因此使它们在作为抗增殖剂治疗癌症和其他疾病方面有用。

  公开号：

  WO2010080474A1

文献信息

• [EN] CATHEPSIN CYSTEINE PROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE PROTÉASES À CYSTÉINE DE TYPE CATHEPSINES
  申请人：MERCK SHARP & DOHME

  公开号：WO2015054038A1

  公开（公告）日：2015-04-16

  This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.

  这项发明涉及一类新型化合物，它们是半胱氨酸蛋白酶抑制剂，包括但不限于对卡特普辛K、L、S和B的抑制剂。这些化合物可用于治疗需要抑制骨吸收的疾病，如骨质疏松症。
• Heterobicyclic pyrazole compounds and methods of use
  申请人：Blake F. James

  公开号：US20070238726A1

  公开（公告）日：2007-10-11

  Compounds of Formulas Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting receptor tyrosine kinases and for treating disorders mediated thereby. Methods of using compounds of Formula Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

  化合物Ia和Ib的结构，以及其立体异构体、几何异构体、互变异构体、溶剂合物、代谢物和药学上可接受的盐，可用于抑制受体酪氨酸激酶并治疗由此介导的疾病。公开了使用化合物Ia和Ib的结构，以及其立体异构体、几何异构体、互变异构体、溶剂合物和药学上可接受的盐的方法，用于体外、体内和体内诊断、预防或治疗哺乳动物细胞中的这类疾病，或相关的病理条件。
• 3-(Piperidin-4-ylmethoxy)pyridine Containing Compounds Are Potent Inhibitors of Lysine Specific Demethylase 1
  作者：Fangrui Wu、Chao Zhou、Yuan Yao、Liping Wei、Zizhen Feng、Lisheng Deng、Yongcheng Song

  DOI：10.1021/acs.jmedchem.5b01361

  日期：2016.1.14

  overexpression. We report the design, synthesis, and structure–activity relationships of 3-(piperidin-4-ylmethoxy)pyridine containing compounds as potent LSD1 inhibitors with Ki values as low as 29 nM. These compounds exhibited high selectivity (>160×) against related monoamine oxidase A and B. Enzyme kinetics and docking studies suggested they are competitive inhibitors against a dimethylated H3K4 substrate

  组蛋白赖氨酸残基的甲基化在基因表达调节以及癌症起始中起重要作用。赖氨酸特异性脱甲基酶1（LSD1）负责维持组蛋白H3赖氨酸4（H3K4）的平衡甲基化水平。由于甲基化的H3K4或LSD1过表达的重要功能，LSD1是某些癌症的药物靶标。我们报告了作为有效LSD1抑制剂的含有3-（哌啶-4-基甲氧基）吡啶的化合物（与K i的设计，合成和结构-活性关系）值低至29 nM。这些化合物对相关的单胺氧化酶A和B表现出高选择性（> 160x）。酶动力学和对接研究表明它们是针对二甲基化H3K4底物的竞争性抑制剂，并提供了可能的结合方式。有效的LSD1抑制剂可以增加细胞H3K4甲基化并强烈抑制EC 50值低至280 nM的几种白血病和实体瘤细胞的增殖，而对正常细胞的作用却微不足道。
• Aryl- and Heteroaryl-Ethyl-Acylguanidine Derivatives, Their Preparation and Their Application in Therapeutics
  申请人：BOCSKEI Jozsef Zsolt

  公开号：US20090203696A1

  公开（公告）日：2009-08-13

  Disclosed are compounds according to formula (I): wherein A, Q, X, Y, Z, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 are as defined herein. The disclosure also relates to pharmaceutical compositions containing a compound of formula (I), to processes for preparing the compounds of formula (I), and to methods of using the compounds of formula (I).

  公开了根据公式(I)的化合物： 其中A、Q、X、Y、Z、R1、R2、R3、R4、R5、R6、R7、R8、R9、R10和R11按本文定义。该披露还涉及包含公式(I)的化合物的药物组合物，制备公式(I)的化合物的方法以及使用公式(I)的化合物的方法。
• Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
  申请人：Castro C. Alfredo

  公开号：US20060025460A1

  公开（公告）日：2006-02-02

  One aspect of the present invention relates to heterocyclic compounds that bind to bcl proteins and inhibit Bcl function. Another aspect of the present invention relates to compositions comprising a heterocyclic compound of the invention. The present invention provides methods for treating and modulating disorders associated with hyperproliferation, such as cancer.

  本发明的一个方面涉及结合到bcl蛋白并抑制Bcl功能的杂环化合物。本发明的另一个方面涉及包含本发明的杂环化合物的组合物。本发明提供了用于治疗和调节与过度增殖相关的疾病，如癌症的方法。